Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?Zacks Investment Research • 09/12/25
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?Zacks Investment Research • 09/05/25
Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?Zacks Investment Research • 09/04/25
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?Zacks Investment Research • 08/18/25
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/07/25
Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant UpsideSeeking Alpha • 06/10/25
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/12/25
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With ServierSeeking Alpha • 03/25/25
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology TherapyGlobeNewsWire • 03/19/25
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/06/25
Black Diamond Therapeutics: Speculative Buy With Precision Oncology CatalystsSeeking Alpha • 12/30/24
Black Diamond (BDTX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 12/11/24
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/05/24
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash RunwayGlobeNewsWire • 10/07/24
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance MutationsGlobeNewsWire • 09/23/24
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLCGlobeNewsWire • 09/22/24
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024GlobeNewsWire • 09/14/24
All You Need to Know About Black Diamond (BDTX) Rating Upgrade to BuyZacks Investment Research • 08/08/24
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/06/24
Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep DiveSeeking Alpha • 06/27/24